In 39 anti-FHL1+ patients with IIM with a total of 210 observations during follow-up, there were no statistically significant associations between anti-FHL1 autoantibody levels, core set measures, disease activity or damage in the mixed effect regression models including measurement from baseline and all available follow-ups. This evidence concerns the gene FHL1 and acquired idiopathic inflammatory myopathy.